Changes in laboratory parameters (n = 92).^a

a<p>All values are expressed as median (interquartile range).</p

Time to virological failure and to treatment discontinuation in HIV-1-infected patients with DRV/r monotherapy.

<p>Abbreviations: 95% CI, 95% Confidence Interval. This figure shows the time to virological failure and time to treatment discontinuation for any reason among patients developing treatment failure during the overall follow-up.</p

Changes in fasting lipid profile in patients switched to DRV/r monotherapy in routine clinical practice (n = 92).

<p>Abbreviations: Total-c, total-cholesterol; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; TG, triglycerides; 95% CI, 95% Confidence Interval.</p

Baseline characteristics.^a

a<p>All values are expressed as No. (%), unless otherwise indicated.</p>b<p>Median (interquartile range).</p><p>Abbreviations: HCV, hepatitis C virus; CDC, Centers for Disease Control and Prevention; ARV, antiretroviral; 3TC/FTC, lamivudine/emtricitabine; TDF, tenofovir; ABC, abacavir; NRTIs, nucleoside reverse transcriptase inhibitors; LPV, lopinavir; ATV, atazanavir; FosAPV, fosamprenavir; DRV, darunavir; SQV, saquinavir; NNRTIs, non-nucleoside reverse transcriptase inhibitors; RAL, raltegravir.</p

Summary of effectiveness results.

<p>Abbreviations: NRTI, nucleoside reverse transcriptase inhibitors; DRV/r, darunavir/ritonavir; OT, optimized treatment.</p

Factors associated with development of dyslipidemia.

<p>Statistically significant results (p<0.05) are in bold.</p><p>Abbreviations: HDL, high-density lipoprotein; LDL, low-density lipoprotein; HCV, hepatitis C virus; ARV, antiretroviral; TDF, tenofovir; ABC, abacavir; NRTIs, nucleoside reverse transcriptase inhibitors; LPV, lopinavir;</p><p>ATV, atazanavir; DRV, darunavir; OR, odds ratio; CI, confidence interval.</p>a<p>Univariate and multivariate logistic regression.</p>b<p>Risk per year.</p

Changes in lipid profile and glycemia and satisfaction.

<p>All values are shown as mean (SD).</p>*<p>P values express intra-group differences between baseline and week 48.</p><p>Between groups, the only differences recorded were for triglycerides (p = 0.04) and glycemia (p = 0.03) at week 24.</p><p>HDL, High density lipoprotein; LDL, Low density lipoprotein.</p>**<p>Patient satisfaction was assessed using two 0–10 likert scales.</p

Baseline epidemiological and HIV-related characteristics.

<p>Parameters are expressed as Median value (IQR 25;75) except when it was specified. HCV, hepatitis C virus; HBV, hepatitis B virus; PI, protease inhibitors; NNRTI, non-nucleoside analog reverse transcriptase inhibitor; RTV, ritonavir; BID, twice daily dosin.</p

Change in cognitive measures at week 48.

<p>Change in cognitive measures at week 48.</p

Demographic and clinical characteristics^a.

a<p>Values are expressed as No. (%) or median (interquartile range).</p>b<p>Standardized T scores based on normative data.</p>c<p>Previous or current disease involving the CNS, psychiatric disorder, psychopharmacologic treatment, and drug use.</p><p>Abbreviations: MSM, men who have sex with men; CDC, Centers for Disease Control and Prevention; ARV, antiretroviral; PIs, protease inhibitors; NRTIs, nucleoside reverse transcriptase inhibitors; NNRTIs, nonnucleoside reverse transcriptase inhibitors; LPV/r, lopinavir/ritonavir; LPV/r-MT, lopinavir/ritonavir monotherapy; LPV/r-ART, lopinavir/ritonavir triple-therapy; TDF, tenofovir; FTC, emtricitabine; ABC, abacavir, 3TC, lamivudine; AZT, zidovudine; ddI, didanosine; VL, viral load; WAIS-III, Wechsler Adult Intelligence Scale-III; Beck Depression Inventory; STAI, State-Trait Anxiety Inventory.</p